Alinejad Vahideh, Dolati Sanam, Motallebnezhad Morteza, Yousefi Mehdi
Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran; Drug Applied Research Center, Tabriz University of Medical Sciences, Tabriz, Iran; Department of Immunology, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran.
Drug Applied Research Center, Tabriz University of Medical Sciences, Tabriz, Iran; Department of Immunology, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran.
Biomed Pharmacother. 2017 Apr;88:795-803. doi: 10.1016/j.biopha.2017.01.120. Epub 2017 Feb 2.
Breast cancer is the most important cause of death in women globally. Though, improved survival is due to the developments in the screening techniques, initial diagnosis, and advances in treatments. Numerous factors contributed in the progression of breast cancer, such as inflammation. The most significant factor involved in the inflammatory process, is T helper 17 (Th17) cells. Th17 cells have an exceptional role in many of inflammatory diseases like psoriasis, rheumatoid arthritis, and breast cancer through production of proinflammatory cytokine (IL17). As the collected indication recommends a possible relevance between chronic inflammation and cancer tumorigenesis, it appears that this cytokine can stimulate the tumorigenesis of breast tumor cells. The IL17 family consist of 6 protein members, among them IL17B and its receptor, and IL17RB signaling pathway plays a key role in development and progression of breast cancer, and targeting this signaling pathway or its specific downstream mediators by a chemotherapy drug and small interfering RNA interference is a potentially novel therapeutic pathway for inhibition of this disease. This comprehensive review details the recognition of activity, signaling, and the roles of IL17B-IL17RB in breast cancer have caused to determination of new therapeutic mechanisms with the purpose of introduction this system and the regulation of its signaling pathway.
乳腺癌是全球女性最重要的死因。不过，生存率的提高得益于筛查技术、初始诊断及治疗进展。许多因素导致乳腺癌进展，比如炎症。炎症过程中涉及的最重要因素是辅助性T细胞17（Th17）。Th17细胞通过产生促炎细胞因子（IL17），在许多炎症性疾病如银屑病、类风湿性关节炎和乳腺癌中发挥特殊作用。鉴于现有证据表明慢性炎症与肿瘤发生之间可能存在关联，这种细胞因子似乎能够刺激乳腺肿瘤细胞的肿瘤发生。IL17家族由6个蛋白质成员组成，其中IL17B及其受体，以及IL17RB信号通路在乳腺癌的发生和发展中起关键作用，通过化疗药物和小干扰RNA干扰靶向该信号通路或其特定下游介质是抑制这种疾病的一种潜在新治疗途径。这篇综述详细阐述了对IL17B - IL17RB在乳腺癌中的活性、信号传导及作用的认识，这促使人们确定新的治疗机制，旨在介绍该系统并调节其信号通路。
